Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2014 May;34(5):2477-80.

Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.

Author information

1
Experimental Medicine Department, Viale Regina Elena 324, University of Rome 'Sapienza', 00161 Roma, Italy. susanna.scarpa@uniroma1.it.

Abstract

Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption and are widely used in the treatment of bone metastases. Osteonecrosis of the jaw (ONJ) is the worst side-effect related to BP use. At our Center, we have implemented internal guidelines regarding the management of patients with bone metastases from solid tumors. Our analysis includes 200 patients affected by solid tumors with bone metastases who received zoledronic acid. They underwent a baseline mouth assessment to evaluate their dental conditions and to perform dental care; a dental follow-up was performed every six months. All patients received calcium and vitamin D daily. Dental examination and application of preventive measures led to a total reduction in ONJ in our patients treated with zoledronic acid. The keystone in management of ONJ is prevention, and the risk of developing ONJ during treatment with zoledronic acid is reduced by implementing preventive measures.

KEYWORDS:

Bisphosphonates; bone metastasis; osteonecrosis of the jaw; zoledronic acid

PMID:
24778063
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center